Breast cancer stage III

4 trials 1 recruiting MedDRA PT
4 Registered trials
1 Recruiting
4 Unique sponsors
9 Unique IMPs
1 Commercial trials
Drug classes (ATC)
— ATC code not specified 1
L Oncology (ATC L) 3
Mechanism of action (INN-stem analysis)
Monoclonal antibody (tumor, humanized) 2 substances
Antibody-drug conjugate (ADC) 2 substances
Platinum compound 2 substances
Monoclonal antibody 1 substance
Taxane 1 substance
Antimetabolite 1 substance
Phase III: 1 Phase II: 3

Filter these 4 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 4 trials

Phase III

1 trial
  • GBG Forschungs GmbH Academic
    CAPECITABINE; CARBOPLATIN; CISPLATIN; SACITUZUMAB GOVITECAN
    2023-510390-33-00 6 countries 2020 n=1,386
    Ended

Phase II

3 trials
  • Jazz Pharmaceuticals Ireland Limited Commercial
    ZANIDATAMAB
    2025-523204-68-00 3 countries 2026 n=100
    Recruiting
  • BOOG Study Center B.V. Academic
    PERTUZUMAB; TRASTUZUMAB; TRASTUZUMAB EMTANSINE
    2024-516205-23-00 1 country 2019 n=472
    Ended
  • Karolinska University Hospital Academic
    DOCETAXEL; PERTUZUMAB; TRASTUZUMAB; TRASTUZUMAB EMTANSINE
    2023-508411-23-00 1 country 2014 n=200
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Jazz Pharmaceuticals Ireland Limited Commercial 1 Phase II 1
BOOG Study Center B.V. Academic 1 Phase II 0
Karolinska University Hospital Academic 1 Phase II 0
GBG Forschungs GmbH Academic 1 Phase III 0
New trials by year
2019
1
2020
1
2026
1
← All indication landscapes